Cargando…

Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes

SIMPLE SUMMARY: We evaluated the short-term effectiveness of a mammography screening program in all women who participated in the screening program and were diagnosed with screen-detected or interval breast cancer (BC) in Flanders (2008–2018). The evaluation was performed for the major molecular sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Lilu, Greuter, Marcel J. W., Truyen, Inge, Goossens, Mathijs, Van der Vegt, Bert, De Schutter, Harlinde, Van Hal, Guido, de Bock, Geertruida H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562677/
https://www.ncbi.nlm.nih.gov/pubmed/36230754
http://dx.doi.org/10.3390/cancers14194831
_version_ 1784808228602773504
author Ding, Lilu
Greuter, Marcel J. W.
Truyen, Inge
Goossens, Mathijs
Van der Vegt, Bert
De Schutter, Harlinde
Van Hal, Guido
de Bock, Geertruida H.
author_facet Ding, Lilu
Greuter, Marcel J. W.
Truyen, Inge
Goossens, Mathijs
Van der Vegt, Bert
De Schutter, Harlinde
Van Hal, Guido
de Bock, Geertruida H.
author_sort Ding, Lilu
collection PubMed
description SIMPLE SUMMARY: We evaluated the short-term effectiveness of a mammography screening program in all women who participated in the screening program and were diagnosed with screen-detected or interval breast cancer (BC) in Flanders (2008–2018). The evaluation was performed for the major molecular subtypes of invasive BC separately and considering the regularity of participation. We found that screen-detected BC was more likely to be diagnosed at early stages than interval BC of luminal, luminal-HER2-positive, and triple-negative BC (TNBC) type, but not for the human epidermal growth factor receptor 2-positive (HER2 positive) subtype. In addition, regular participation was related to a higher likelihood of screening detection than irregular participation for luminal, luminal-HER2-positive, and TNBC, but not for the HER2 positive subtype, either. Our results indicate that regular screening as compared to irregular screening is effective for all breast cancers except for the HER2 subtype. ABSTRACT: Background: Screening program effectiveness is generally evaluated for breast cancer (BC) as one disease and without considering the regularity of participation, while this might have an impact on detection rate. Objectives: To evaluate the short-term effectiveness of a mammography screening program for the major molecular subtypes of invasive BC. Methods: All women who participated in the screening program and were diagnosed with screen-detected or interval BC in Flanders were included in the study (2008–2018). Molecular subtypes considered were luminal and luminal-HER2-positive, human epidermal growth factor receptor 2-positive, and triple-negative BC (TNBC). The relationship between the BC stage at diagnosis (early (I–II) versus advanced (III–IV)) and the method of detection (screen-detected or interval) and the relationship between the method of detection and participation regularity (regular versus irregular) were evaluated by multi-variable logistic regression models. All models were performed for each molecular subtype and adjusted for age. Results: Among the 12,318 included women, BC of luminal and luminal-HER2-positive subtypes accounted for 70.9% and 11.3%, respectively. Screen-detected BC was more likely to be diagnosed at early stages than interval BC with varied effect sizes for luminal, luminal-HER2-positive, and TNBC with OR:2.82 (95% CI: 2.45–3.25), OR:2.39 (95% CI: 1.77–3.24), and OR:2.29 (95% CI: 1.34–4.05), respectively. Regular participation was related to a higher likelihood of screening detection than irregular participation for luminal, luminal-HER2-positive, and TNBC with OR:1.21 (95% CI: 1.09–1.34), OR: 1.79 (95% CI: 1.38–2.33), and OR: 1.62 (95% CI: 1.10–2.41), respectively. Conclusions: Regular screening as compared to irregular screening is effective for all breast cancers except for the HER2 subtype.
format Online
Article
Text
id pubmed-9562677
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95626772022-10-15 Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes Ding, Lilu Greuter, Marcel J. W. Truyen, Inge Goossens, Mathijs Van der Vegt, Bert De Schutter, Harlinde Van Hal, Guido de Bock, Geertruida H. Cancers (Basel) Article SIMPLE SUMMARY: We evaluated the short-term effectiveness of a mammography screening program in all women who participated in the screening program and were diagnosed with screen-detected or interval breast cancer (BC) in Flanders (2008–2018). The evaluation was performed for the major molecular subtypes of invasive BC separately and considering the regularity of participation. We found that screen-detected BC was more likely to be diagnosed at early stages than interval BC of luminal, luminal-HER2-positive, and triple-negative BC (TNBC) type, but not for the human epidermal growth factor receptor 2-positive (HER2 positive) subtype. In addition, regular participation was related to a higher likelihood of screening detection than irregular participation for luminal, luminal-HER2-positive, and TNBC, but not for the HER2 positive subtype, either. Our results indicate that regular screening as compared to irregular screening is effective for all breast cancers except for the HER2 subtype. ABSTRACT: Background: Screening program effectiveness is generally evaluated for breast cancer (BC) as one disease and without considering the regularity of participation, while this might have an impact on detection rate. Objectives: To evaluate the short-term effectiveness of a mammography screening program for the major molecular subtypes of invasive BC. Methods: All women who participated in the screening program and were diagnosed with screen-detected or interval BC in Flanders were included in the study (2008–2018). Molecular subtypes considered were luminal and luminal-HER2-positive, human epidermal growth factor receptor 2-positive, and triple-negative BC (TNBC). The relationship between the BC stage at diagnosis (early (I–II) versus advanced (III–IV)) and the method of detection (screen-detected or interval) and the relationship between the method of detection and participation regularity (regular versus irregular) were evaluated by multi-variable logistic regression models. All models were performed for each molecular subtype and adjusted for age. Results: Among the 12,318 included women, BC of luminal and luminal-HER2-positive subtypes accounted for 70.9% and 11.3%, respectively. Screen-detected BC was more likely to be diagnosed at early stages than interval BC with varied effect sizes for luminal, luminal-HER2-positive, and TNBC with OR:2.82 (95% CI: 2.45–3.25), OR:2.39 (95% CI: 1.77–3.24), and OR:2.29 (95% CI: 1.34–4.05), respectively. Regular participation was related to a higher likelihood of screening detection than irregular participation for luminal, luminal-HER2-positive, and TNBC with OR:1.21 (95% CI: 1.09–1.34), OR: 1.79 (95% CI: 1.38–2.33), and OR: 1.62 (95% CI: 1.10–2.41), respectively. Conclusions: Regular screening as compared to irregular screening is effective for all breast cancers except for the HER2 subtype. MDPI 2022-10-03 /pmc/articles/PMC9562677/ /pubmed/36230754 http://dx.doi.org/10.3390/cancers14194831 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ding, Lilu
Greuter, Marcel J. W.
Truyen, Inge
Goossens, Mathijs
Van der Vegt, Bert
De Schutter, Harlinde
Van Hal, Guido
de Bock, Geertruida H.
Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes
title Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes
title_full Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes
title_fullStr Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes
title_full_unstemmed Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes
title_short Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes
title_sort effectiveness of organized mammography screening for different breast cancer molecular subtypes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562677/
https://www.ncbi.nlm.nih.gov/pubmed/36230754
http://dx.doi.org/10.3390/cancers14194831
work_keys_str_mv AT dinglilu effectivenessoforganizedmammographyscreeningfordifferentbreastcancermolecularsubtypes
AT greutermarceljw effectivenessoforganizedmammographyscreeningfordifferentbreastcancermolecularsubtypes
AT truyeninge effectivenessoforganizedmammographyscreeningfordifferentbreastcancermolecularsubtypes
AT goossensmathijs effectivenessoforganizedmammographyscreeningfordifferentbreastcancermolecularsubtypes
AT vandervegtbert effectivenessoforganizedmammographyscreeningfordifferentbreastcancermolecularsubtypes
AT deschutterharlinde effectivenessoforganizedmammographyscreeningfordifferentbreastcancermolecularsubtypes
AT vanhalguido effectivenessoforganizedmammographyscreeningfordifferentbreastcancermolecularsubtypes
AT debockgeertruidah effectivenessoforganizedmammographyscreeningfordifferentbreastcancermolecularsubtypes